TrialInvestigational new drugs2025

Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.

Lixia Ma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.